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Structured Summary 45 
 46 
Objectives: To report clinical and laboratory features, treatment responses and outcome in 47 
dogs diagnosed with canine sterile steroid-responsive lymphadenitis in the United Kingdom. 48 
 49 
Methods: Medical records of dogs diagnosed with canine sterile steroid-responsive 50 
lymphadenitis from 2009 to 2016 at six specialist referral centres were evaluated 51 
retrospectively.  52 
 53 
Results: The study included 49 dogs. springer spaniels appeared to be over-represented 54 
(16/49 dogs). Young dogs (median age 3 years and 9 months) and females (31/49) were 55 
frequently affected. Clinical presentation was variable, with pyrexia (39/49), lethargy (35/49) 56 
and anorexia (21/49) being the most commonly reported clinical signs. Lymph node cytology 57 
and/or histopathology demonstrated neutrophilic, pyogranulomatous, granulomatous or 58 
necrotizing lymphadenitis without a detectable underlying cause in all cases.  59 
 60 
As a sterile immune-mediated aetiology was suspected, all dogs received prednisolone with a 61 
subsequent rapid resolution of clinical signs and the lymphadenopathy in most of the cases.  62 
 63 
Clinical significance: Canine sterile steroid-responsive lymphadenitis should be considered 64 
in dogs with pyrexia of unknown origin with inflammatory lymphadenopathy when no 65 
underlying cause can be found and often responds well to therapy with immunosuppressive 66 
corticosteroids.  67 
 68 
 69 
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  73 
Introduction 74 
Lymph node enlargement or lymphadenopathy is often encountered during physical 75 
examination in canine patients (Thangapandiyan et al, 2010). Lymph node enlargement is 76 
categorised into solitary (single lymph node), regional (chains of lymphatic nodes draining a 77 
specific anatomic region) or generalised (multicentric lymph node enlargement affecting 78 
multiple anatomic regions) lymphadenopathy. The causes of lymph node enlargement include 79 
oedema, reactive hyperplasia, inflammation, infection and neoplasia (Sapierzynski et al, 80 
2009). Fine needle aspiration cytology (FNAC) is a valuable diagnostic test to investigate the 81 
cause of lymph node enlargement due to its low cost, simplicity and rapid results (Cowell et 82 
al, 2003).  83 
The normal cell distribution on cytological evaluation of the lymph node is reported to be 85-84 
90% of small lymphocytes, <10% of medium-sized and large lymphocytes, <3% of plasma 85 
cells, and rare neutrophils, eosinophils and macrophages (MacNeill, 2011).  86 
Lymphadenitis is defined as an infiltration of one or more non-lymphoid inflammatory cells 87 
in a lymph node (Teske, 2014). Neutrophilic lymphadenitis, also called purulent or 88 
suppurative lymphadenitis, is characterised by a neutrophil population exceeding 5% of the 89 
cellular population within a lymph node (Raskin et al, 2016). It may be associated with 90 
bacterial, neoplastic or immune-mediated diseases. Granulomatous lymphadenitis is 91 
diagnosed when the percentage of histiocytic cells is greater than 2% of the total cell 92 
population in a lymph node. Pyogranulomatous lymphadenitis is considered when lymph 93 
nodes contain mixed inflammation comprised of increased numbers of neutrophils and 94 
macrophages (McNeill, 2011). Pyogranulomatous lymphadenitis can be associated with 95 
fungal, mycobacterial and neorickettsial infections, leishmaniasis, bartonellosis, 96 
prothotecosis, juvenile cellulitis, vasculitis and idiopathic lymphadenitis (Ishida, 2017; 97 
Raskin et al, 2016). There is a small number of cases reported with sterile lymphadenitis but 98 
this disease is currently poorly understood (Day, 1996; Hoffmann et al, 2002). These cases 99 
can often present with pyrexia.  100 
 101 
Pyrexia, or fever, is defined as increased body temperature due to an elevation of the thermal 102 
set point in the anterior hypothalamus secondary to pyrogen release (Ramsey et al, 2017). 103 
Fever of unknown origin (FUO) is a major diagnostic challenge in both human and veterinary 104 
medicine (Chervier et al, 2012). Although the human literature is relatively complete 105 
regarding FUO, there are few studies in the veterinary literature to explore the more common 106 
causes of canine FUO (Battersby et al, 2006; Chervier et al, 2012; Dunn et al, 1998). 107 
The aim of this study was to report the clinical presentation, diagnostic testing, treatment 108 
response and outcome of canine sterile steroid-responsive lymphadenitis (CSSRL), which is 109 
not well described in the veterinary literature.  110 
 111 
 112 
  113 
Materials and Methods 114 
The medical records of dogs diagnosed with canine sterile steroid-responsive lymphadenitis 115 
from 2009 to 2016 at six specialist referral centres in the United Kingdom (UK) were 116 
retrospectively evaluated. The data from each institution was retrieved via searches of 117 
practice management systems with computerised and paper-based records. Collaboration 118 
between institutions was achieved by completing a standardised spreadsheet. Data collected 119 
included signalment, history (including time to referral and pre-referral treatment), physical 120 
examination findings (including lymph node size and distribution), clinical pathology data 121 
(including results of lymph node cytology and/or histopathology and infectious disease 122 
screening), diagnostic imaging results, treatment and outcome (including time to relapse, 123 
repeat treatment). Pyrexia was defined as a temperature >39.2°C. Dogs with incomplete 124 
medical records were excluded. The study was approved by the ethics committee of the 125 
School of Veterinary Medicine and Science, University of Nottingham. 126 
 127 
Case inclusion criteria required a diagnosis of lymphadenitis either with cytology, 128 
histopathology or both in which no underlying cause was identified and a positive response to 129 
treatment with glucocorticoids . Dogs that clinically improved on treatment with 130 
antimicrobial agents were excluded. When cytology was performed, neutrophilic 131 
lymphadenitis was diagnosed when the neutrophil population in the lymph node was >5%; 132 
granulomatous lymphadenitis was diagnosed when histiocytic cells comprised >2% of the 133 
lymph node population and pyogranulomatous lymphadenitis was diagnosed when there was 134 
a mixed inflammatory infiltrate with increased numbers of neutrophils and macrophages 135 
within the lymph node; necrotizing lymphadenitis was diagnosed when there was 136 
neutrophilic or histiocytic inflammation accompanied by necrosis within the lymph node; 137 
reactive hyperplasia was diagnosed when there were increased numbers (15-30%) of medium 138 
and large lymphocytes with increased numbers of plasma cells (Raskin, 2016).  When 139 
histopathology was performed, the type of lymphadenitis was established based on the 140 
predominant cell present, its distribution within the lymph node and the quality and character 141 
of the neutrophil nuclei and the presence of granulomas/pyogranulomas (Valli, 2016). 142 
Diagnostic investigations in each case excluded other potential causes of lymphadenopathy 143 
such as infectious, other inflammatory and neoplastic causes. In all cases, haematology, 144 
biochemistry, urinalysis, urine culture, thoracic radiographs and abdominal ultrasound were 145 
performed. When appropriate, echocardiography, abdominal radiographs, arthrocentesis with 146 
synovial fluid analysis and culture, cerebrospinal fluid analysis, tests for arthropod borne 147 
diseases including Ehrlichia canis, Anaplasma phagocytophilum, Anaplasma platys, Borrelia 148 
burgdorferi, Leishmania infantum and Bartonella henselae, lymph node culture, Ziehl 149 
Neelsen and Periodic acid-Schiff (PAS) staining of lymph node FNAC aspirates, 150 
bronchoscopy and bronchoalveolar lavage cytological analysis and culture, computed 151 
tomography (CT), magnetic resonance imaging (MRI), C-reactive protein (CRP), pleural or 152 
peritoneal fluid cytological analysis, FNAC of liver or spleen, skin biopsies, faecal analysis, 153 
exploratory laparotomy and haemoculture were also performed.  154 
All the cases were treated with glucocorticoids, with gradual dose decreases over the 155 
following weeks to months depending on response. Clinical reassessment was performed 156 
regularly and response to treatment assessed on the basis of owner’s perception of clinical 157 
signs and physical examination (resolution of the pyrexia if present, resolution or 158 
improvement of the lymphadenopathy by more than a 50% reduction of the lymph node size 159 
if assessable or improvement of the dog’s demeanour). In some cases diagnostic imaging was 160 
repeated to assess for resolution of lymphadenopathy (if not externally assessable) or 161 
measurement of C-reactive protein if it was measured initially and was elevated. Follow-up 162 
was considered when the animal died or based on clinical impression in the cases that 163 
progressed adequately.  164 
 165 
  166 
Results 167 
Canine sterile steroid-responsive lymphadenitis was diagnosed in the forty-nine dogs enrolled 168 
in this study. These included nineteen different breeds as well as 7 mixed-breed dogs. English 169 
Springer spaniels (16/49) were the most common breed followed by cocker spaniels (4/49), 170 
Border collies (3/49), German shepherds (2/49) and beagles (2/49).  (Table 1) 171 
The median age at presentation was 3 years and 9 months (range 6 months to 10 years).  172 
Thirty-one of the dogs were female (62%; 40% neutered) and 18 were male (36%; 18% 173 
neutered). There were no significant differences between English springer spaniels and other 174 
breeds with regard to age (median 44 months versus 44.7 months) and sex (female 58.8%, 175 
60% neutered versus 68.7%; 72.7% neutered).  176 
Previous history included idiopathic epilepsy in 2 dogs, intervertebral disc disease in one dog, 177 
previous septic peritonitis in one dog, hamartoma in the right hip and otitis in one dog and 178 
protein losing nephropathy and spontaneous (resolved) haemothorax in another dog. 179 
 180 
Prior to referral, 45 dogs received antimicrobial and/or anti-inflammatory therapy without a 181 
significant clinical response. Forty-one dogs were treated with antimicrobials which included 182 
co-amoxiclav (31/41) metronidazole (7/41), enrofloxacin (6/41), doxycycline (6/41), 183 
marbofloxacin (5/41), cephalexin (4/41), clindamycin (1/41) and pradofloxacin (1/41). 184 
Twenty-eight dogs received non-steroidal anti-inflammatories (NSAIDs) which included 185 
meloxicam (20/28), carprofen (7/28) and firocoxib (1/28). Five dogs were treated with an 186 
anti-inflammatory dose of glucocorticoids (0.5-1mg/kg/once a day) including 4 dogs treated 187 
with prednisolone, and 1 dog treated with methylprednisolone. Nine of the 45 dogs that 188 
received treatment prior to referral presentation had a partial clinical response, this included 3 189 
dogs treated with antimicrobials and NSAIDs, 3 dogs receiving antimicrobials and 190 
glucocorticoids, 2 dogs only receiving antimicrobials and 1 dog receiving glucocorticoids. 191 
Five of the forty-nine dogs did not receive any medication prior to referral. Median time to 192 
referral (TTR) was 30 days (range 2 to 90 days).  193 
 194 
Clinical presentation varied widely between animals but the most common clinical signs 195 
were pyrexia (39/49), lethargy (30/49) and anorexia (21/49). Other clinical signs are 196 
summarised in table 2. Thirty-three animals were pyrexic at presentation, with a median 197 
rectal temperature of 39.9°C (range 39.1°C-40.9°C).  198 
 199 
Although lymphadenopathy was grossly palpable in most cases, eleven animals presented 200 
without any external sign of lymphadenopathy, but thoracic and intraabdominal 201 
lymphadenopathy was later diagnosed through further investigation.  In four cases there was 202 
only one lymph node affected (inguinal in one case, retropharyngeal in two cases and 203 
mandibular in one case) and in the remaining forty-five cases there were multiple lymph 204 
nodes affected. The mandibular (31/49), superficial cervical (22/49 and popliteal (20/49) 205 
lymph nodes were most commonly affected. Objective measurements of the lymph nodes 206 
were not available in many cases; however, subjectively lymphadenopathy ranged from mild 207 
to marked. Intra-thoracic and intra-abdominal lymphadenopathy was documented with 208 
diagnostic imaging (thoracic radiographs, abdominal radiographs, abdominal ultrasound, CT 209 
or MRI) performed or interpreted by boarded radiologists. Intrathoracic lymphadenopathy 210 
was noted in 4 of the 49 cases affecting the sternal (2/49) and tracheobronchial (2/49) lymph 211 
nodes. Other changes on thoracic imaging included the presence of a mild to moderate 212 
bronchointerstitial pattern in 3 dogs, focal alveolar infiltrate in 2 dogs and nodular pattern in 213 
one dog. Bronchoalveolar lavage cytological analysis included mixed inflammation with a 214 
negative culture in all dogs that presented with radiographic changes on thoracic imaging. 215 
Intraabdominal lymphadenopathy was documented in 25 of the 49 dogs affecting the 216 
mesenteric (15/25), medial iliac (9/25) and sublumbar (1/25) lymph nodes. Other changes on 217 
abdominal imaging included the presence of minimal volume abdominal effusion in 5 dogs, 218 
mild splenomegaly in 4 dogs and hepatomegaly in 3 dogs. In 2 dogs analysis of the peritoneal 219 
fluid revealed the presence of a neutrophilic transudate with negative culture. Splenic FNAC 220 
revealed reactive hyperplasia in 3 of the 4 dogs with splenomegaly and hepatic FNAC 221 
documented mild vacuolar change and mild neutrophilic inflammation in one dog. 222 
 223 
Main clinicopathological findings included mild, non-regenerative anaemia (haematocrit 224 
0.31-0.35L/L; RI: 0.37-0.55) in 5 cases (10%), mild to moderate neutrophilic leucocytosis 225 
(neutrophil count 20-35x109/L; RI: 3-11.5x109/L) in 11 cases (22%), monocytic leucocytosis 226 
(monocyte count 1.7-6.7x109/L; RI: 0.2-1.4) in 4 cases (8%), neutrophilic and monocytic 227 
leucocytosis in 4 cases (8%) and moderate regenerative anaemia (HCT: 0.17L/L; RI: 0.37-228 
0.55) and severe thrombocytopenia in one case (2%). Main biochemical abnormalities 229 
included mild to moderate elevation in alkaline phosphatase activity (ALP: 154-600IU/L; RI: 230 
14-105) in 8 cases (16%), mild to moderate hypoalbuminaemia (albumin values 16-21g/l; RI: 231 
25-40) in 4 cases (8%) and mild hyperglobulinaemia (globulin values 47-52g/l; RI: 23-45) in 232 
2 cases (4%).  233 
Arthropod-borne disease testing was performed in 37 of the cases (74%) and of these, 100% 234 
of the cases were tested for Borrelia burgdorferi with serology, 34 cases (91.9%) were tested 235 
for Bartonella henselae with PCR from blood, 9 cases (24.3%) were tested for Anaplasma 236 
phagocytophilum with PCR from blood, 4 cases (10.8%) were tested for Ehrlichia canis with 237 
PCR of blood and 1 case (2.7%) was tested for Leishmania infantum with serology. All the 238 
results were negative. 239 
Arthrocentesis and subsequent synovial fluid cytological analysis and culture was performed 240 
in 9 out of 49 cases (18%) as part of a FUO work-up; from which 4 (44.4%) were considered 241 
normal, 4 (44.4%) showed marked neutrophilic inflammation and 1 (11.1%) showed mild 242 
neutrophilic inflammation. All the cultures were negative. 243 
Cerebrospinal fluid analysis was performed in 7 out of 49 cases (14%). This was performed 244 
in 2 dogs because of lumbosacral pain, in 2 dogs as part of FUO work-up, in 1 dog because of 245 
neck pain, in 1 dog because of ataxia and in 1 dog because of stiff gait. Cerebrospinal fluid  246 
was cytologically normal in 6 dogs (85.7%) and revealed neutrophilic and lymphocytic 247 
inflammation in one dog (14.3%).  248 
CRP was assessed in 6 out of 49 cases and was elevated in all (range 84.1-689mg/L; 249 
reference interval <10mg/L). 250 
 251 
In all dogs, a diagnosis of lymphadenitis was reached with cytology and/or histopathology 252 
(Tables 3 and 4). Cytological assessment was performed in 44 of the 49 dogs, histological 253 
assessment in 27 of the 49 dogs and both in 21 dogs. The predominant type of lymphadenitis 254 
diagnosed on cytology was neutrophilic (28/44), followed by pyogranulomatous (6/44), 255 
granulomatous (5/44) and reactive hyperplasia (5/44). Conversely, the predominant type of 256 
lymphadenitis diagnosed on histology was pyogranulomatous (13/27) followed by 257 
neutrophilic (8/27), necrotizing (4/27) and granulomatous (2/27). In the cases in which both 258 
cytology and histopathology was performed, good agreement was found in seven of the 21 259 
cases, whereas in the remaining 14 cases cytological diagnosis differed from histological 260 
diagnosis. In eight cases with a cytological classification of neutrophilic lymphadenitis, five 261 
were classified as pyogranulomatous lymphadenitis and three as necrotizing lymphadenitis 262 
on histology. In the five dogs classified as reactive hyperplasia based on cytology, two were 263 
classified as neutrophilic lymphadenitis, one as pyogranulomatous lymphadenitis, one as 264 
granulomatous lymphadenitis and one as necrotizing lymphadenitis on histology. In one case 265 
classified as having pyogranulomatous lymphadenitis on cytology, neutrophilic 266 
lymphadenitis was identified on histology and one dog with granulomatous lymphadenitis on 267 
cytology was classified as having pyogranulomatous lymphadenitis on histology. Culture of 268 
lymph node tissue or aspirates was performed in 28 dogs and was negative in all instances.  269 
Four of the 49 cases were diagnosed with other concurrent immune mediated diseases. One 270 
dog had concurrent immune mediated anaemia (IMHA) and immune mediated 271 
thrombocytopenia (ITP) one dog had concurrent immune mediated polyarthritis (IMPA), one 272 
dog was diagnosed with concurrent IMPA and meningitis and one dog was diagnosed with 273 
concurrent IMPA and pyogranulomatous skin nodules. 274 
 275 
All the animals were treated with corticosteroids. Prednisolone was the first line treatment 276 
chosen in 47 of the 49 dogs, of which 34 dogs were started on 1mg/kg per day (dose range 277 
0.5-3mg/kg per day). One of the 49 dogs was started with dexamethasone (dose 0.2mg/kg per 278 
day) and later was transitioned to prednisolone. Only one of the 49 dogs initially responded 279 
to antimicrobial therapy (co-amoxiclav), but it relapsed four weeks after stopping therapy, 280 
and was subsequently started on prednisolone, with rapid improvement in clinical signs.  281 
Forty-seven of the forty-nine animals (96%) showed marked improvement in clinical 282 
condition, decrease in pyrexia and decrease in lymphadenopathy within 12-48 hours of 283 
initiation of corticosteroid administration. The subsequent treatment protocol followed in 284 
each case was different due to the multicentre retrospective nature of this study, but overall, a 285 
decrease of 25-50% of the prednisolone dose was scheduled every 2-4 weeks, continuing 286 
treatment for at least 3-6 months.  287 
 288 
In nine of the 49 dogs, additional immunosuppressive treatments were used in combination 289 
with prednisolone. Of these nine cases, four received azathioprine (2mg/kg/SID in three cases 290 
and 2mg/kg/EOD in one case), two ciclosporin (5mg/kg/SID), one cyclophosphamide 291 
(250mg/m2 once), one mycophenolate (30mg/kg/EOD) and one chlorambucil (2mg total dose 292 
SID). In five of the cases, additional immunosuppressives were used at the time of recurrence 293 
of clinical signs, whereas in four of the cases they were used initially to decrease the side 294 
effects related to the corticosteroids. The most common adverse effects of corticosteroids 295 
reported were those commonly attributed to this medication, including polyuria, polydipsia, 296 
polyphagia and lethargy. Other less common adverse effects included alopecia, muscle 297 
atrophy, gastrointestinal clinical signs and wound infections.  298 
 299 
In terms of outcome, median follow up was 168 days (range 8 days to 108 months); 22 of 49 300 
dogs were not receiving medication and had no clinical signs after stopping medication. Eight 301 
of 49 dogs were still receiving tapering doses of prednisolone without a relapse detected three 302 
months after diagnosis. One of 49 dogs remained on 0.35mg/kg of prednisolone every other 303 
day. Due to the multi centre nature of the study, and the fact that many dogs continued their 304 
care at their primary veterinary clinic, 13 dogs were lost to follow-up whilst receiving 305 
decreasing doses of prednisolone. Five of 49 dogs had an initial good response to treatment; 306 
however they died or  were euthanized during or after treatment. The cause of death was 307 
unknown in these dogs and no post-mortem examination information was available..  308 
 309 
Eighteen dogs had a recurrence of their clinical signs during the study period of which 13 310 
were springer spaniels. The average time to return of clinical signs was 19 weeks after 311 
diagnosis. In 12 of the 18 cases, prednisolone had been withdrawn before the time of 312 
recurrence of clinical signs whereas the rest were still on tapering doses of corticosteroids. 313 
Two dogs were monitored without adding further treatment and they did not show further 314 
progression of signs. Fourteen dogs recommenced increased doses of prednisolone, which 315 
resulted in resolution of the clinical signs and the lymphadenopathy. Two other dogs had two 316 
episodes of return of clinical signs of which one responded well to re-treatment with 317 
prednisolone on each occasion while the other responded well on the first occasion but not 318 
the second. In one of the 18 cases with recurrence of clinical signs there was a rapid decrease 319 
in prednisolone dose over 3-4 weeks the rest had a reduction over 3-6 months.  320 
 321 
Relating outcome with cytological/histological diagnosis, of the 22 dogs that were clinically 322 
well without treatment, 10 had neutrophilic lymphadenitis, 10 had pyogranulomatous 323 
lymphadenitis, one had granulomatous lymphadenitis and one had necrotizing lymphadenitis. 324 
Of the five cases that were euthanized or died, two had neutrophilic lymphadenitis and three 325 
(50%) had pyogranulomatous lymphadenitis.  326 
 327 
Twelve of the 22 dogs that were well after discontinuing treatment presented initially with 328 
external lymphadenopathy, six dogs with internal lymphadenopathy and four had both 329 
internal and external lymphadenopathy. Of the five dogs that were euthanized or died, four 330 
had external lymphadenopathy and 1 had documented internal and external 331 
lymphadenopathy.  332 
 333 
Discussion 334 
This study describes sterile steroid-responsive lymphadenitis (CSSRL) as a cause of 335 
lymphadenopathy and FUO in dogs, its medical management and treatment outcomes. To the 336 
authors’ knowledge, primary sterile lymphadenitis without evidence of other diseases has not 337 
been well described in the veterinary literature.  338 
Dogs in this study were mainly presented for pyrexia, lethargy and inappetence; varying 339 
degrees of peripheral or internal lymphadenopathy were subsequently documented.  340 
Lymphadenopathy is encountered in many disease processes and determining the cause of 341 
lymphadenopathy can require time-consuming and expensive investigations. Thorough 342 
diagnostic investigations were performed in all the patients that were recruited for this study; 343 
however, several diagnostic evaluations performed were different between cases due to the 344 
different clinical presentations and clinicians involved. Investigations in all the cases failed to 345 
find an underlying infectious (bacterial [Bartonella, Mycobacteria, Rickettsia, Ehrlichia, other 346 
Gram positives or negatives], protozoal [Leishmaniasis] or fungal), neoplastic or another 347 
inflammatory condition. All the animals that had tissue samples submitted for culture (lymph 348 
node, blood, urine, bronchoalveolar lavage fluid, synovial fluid or cerebrospinal fluid) 349 
showed no bacterial growth; however, this particular point is difficult to fully characterise, as 350 
many animals were pre-treated with antimicrobials, which could preclude the growth or 351 
bacterial organisms. On the other hand, the fact that many of these animals were treated with 352 
antimicrobials and showed no clinical improvement and responded well to steroid therapy 353 
would suggest that an infectious aetiology was unlikely. 354 
 355 
In this UK population of dogs with CSSRL it appears that females were more affected 356 
compared to males (31 females and 18 males). This finding is similar to findings in other 357 
immune mediated diseases such as IMHA or ITP being also overrepresented in female dogs 358 
in some studies (Carr et al, 2002; O’Marra et al, 2011; Putsche & Kohn, 2008; Weinkle et al, 359 
2005).  360 
 361 
Median age at initial presentation was 3 years and 9 months, with ages ranging from 6 362 
months to 10 years. This is similar to the age incidence of other primary immune mediated 363 
diseases, for example IMPA, being more prevalent in young adult dogs (Johnson & Mackin, 364 
2012) 365 
 366 
The most frequent clinical signs documented were lethargy, pyrexia and inappetence. In 367 
addition, a small number of dogs presented with neck pain and abdominal pain, both of which 368 
could account for anorexia. Respiratory signs were present in several cases: 7 animals 369 
presented with cough and 2 animals were dyspnoeic. One dog developed severe respiratory 370 
complications (acute onset dyspnoea) soon after initiating treatment with corticosteroids but 371 
in most of them the thoracic abnormalities resolved after starting treatment. This cause of the 372 
respiratory decompensation in this dog remains uncertain, but some of the changes noted 373 
could be vasculitis-related or potentially a secondary sequelae of the underlying primary 374 
immune-mediated disease process or a pulmonary thromboembolism. Therefore, even if 375 
pyrexia, inappetence and lethargy are the most common clinical signs according to the cases 376 
studied here, a variety of other clinical signs can be present with this condition. Additionally, 377 
concurrent immune mediated conditions such as IMHA, ITP, IMPA and meningitis were 378 
detected in 4 individual cases. Lymphadenopathy in these four dogs may be part of a reactive 379 
process secondary to these individual primary immune-mediated lymphadenitis or part of a 380 
multi-systemic immune mediated condition. This would be further supported by the fact that 381 
these dogs had generalized external and even internal lymphadenopathy rather than local 382 
lymphadenopathy from the affected areas. These cases did not appear to require higher doses 383 
of glucocorticoids in this study population compared with the cases that did not had 384 
concurrent diseases.  385 
 386 
Regarding the lymphadenopathy, it was not restricted to peripheral lymph nodes, and in 387 
certain cases there were no signs of peripheral lymphadenopathy. From the results we 388 
obtained, mandibular, superficial cervical and popliteal lymph nodes were the lymph nodes 389 
that were most frequently affected. Also, these are the lymph nodes more readily palpated on 390 
general physical examination. Regarding outcome, there was no relationship noted between 391 
the number of nodes affected or their location as to outcome or response to treatment.  392 
 393 
In all dogs, a diagnosis of lymphadenitis was reached with lymph node cytology and/or 394 
histopathology. Based on cytology, the predominant type of lymphadenitis was neutrophilic, 395 
whereas the predominant type of lymphadenitis that was documented from the histopathology 396 
samples was pyogranulomatous. The discrepancy between cytology and histopathology may 397 
be attributable to the fact that sections obtained for histopathology may have been more 398 
representative samples, particularly as they would have preserved the architecture of the 399 
lymph node. However, the type of inflammation present did not appear to alter overall 400 
outcome for dogs in this study.  401 
 402 
Prednisolone was the first line immunosuppressive treatment chosen for most dogs, of which 403 
34 dogs commenced with 1mg/kg dose per day (dose range 0.5-3mg/kg per day). Due to the 404 
inherent difficulties with a retrospective study from a multi-centre database, the reasoning for 405 
the starting doses and protocol of continuation of treatment was difficult to establish. Forty-406 
seven dogs showed marked improvement in clinical condition, decrease in pyrexia and 407 
decrease in lymphadenopathy within 12-48 hours of initiation of corticosteroid 408 
administration. In six of the cases, CRP concentration was used for monitoring response to 409 
the treatment and the values normalised when there was clinical improvement. Animals had 410 
previously received intravenous fluid therapy, non-steroidal anti-inflammatories, and 411 
antimicrobials of varying classes, all of which had showed minimal improvement and when 412 
started on corticosteroids their clinical signs improved dramatically within 12-48 hours. One 413 
case initially responded to antimicrobial therapy, but it relapsed four weeks after stopping the 414 
therapy, and was subsequently commenced prednisolone therapy, which immediately 415 
improved its clinical signs. It is uncertain if there was non-detected infectious aetiology or if 416 
its apparent response was a consequence of the waxing and waning nature of immune-417 
mediated disease. 418 
Eighteen dogs (36%) had recurrence of clinical signs during the study period, of which 13 419 
were English springer spaniels. Only one dog that relapsed had a shorter treatment period 420 
before relapse (3-4 weeks) compared to the other cases (3-6 months), making a short duration 421 
of treatment an unlikely reason for relapse in the majority cases. This could suggest that 422 
particularly in English springer spaniels with over 70% of this breed relapsing within the time 423 
period of this study, a longer tapering period of corticosteroids could be necessary and 424 
owners should be warned that a relapse may be more likely in the breed.  425 
 426 
A minority of animals (9/49; 18%) required a second line immunosuppressive medication in 427 
order to either control the lymphadenitis (5/9) when they relapsed or reduce the adverse 428 
effects of corticosteroids (4/9).  429 
 430 
Sixteen of the forty-nine cases in this study were English springer spaniels, which could 431 
suggest a breed predisposition. A case of sterile neutrophilic-macrophagic lymphadenitis 432 
associated with nodular panniculitis in a springer spaniel has been previously reported 433 
(Dandrieux et al, 2011). Indeed, a journal letter published in 2002 also reported a number of 434 
springer spaniels presenting with generalised lymphadenopathy consistent with 435 
granulomatous necrotising lymphadenitis and pyrexia with or without pyogranulomatous 436 
dermatitis (Hoffman et al, 2002). Moreover, English springer spaniels (among other breeds) 437 
have also been reported to be affected by a rare form of mineral-associated lymphadenopathy 438 
(Day, 1996). Nineteen breeds were represented in this study, three of which were spaniel 439 
breeds (English springer spaniel, cocker spaniel and Cavalier King Charles spaniel). It has 440 
been well documented that there is a breed predilection for IMHA in Springer Spaniels and 441 
cocker spaniels (Weinkle et al, 2005; Reimer et al, 1999), whether any links to susceptibility 442 
to immune-mediated disease could be extrapolated from this study remain to be evaluated 443 
and could provide an area for future work.  444 
This study was limited by issues inherent to most retrospective studies, including mainly a 445 
lack of uniformity of the diagnostic investigations and the treatment plans. The diagnostic 446 
work-up was not always the same because the cases were seen during different periods of 447 
time and by different clinicians from different referral centres. Also, the varied presentations 448 
of the cases initially guided investigations based on the clinical signs presented. For the same 449 
reason, some of the cases were lost in follow-up, which makes difficult to interpret the long-450 
term response or outcome of the dogs with this condition. 451 
To the authors’ knowledge, primary sterile lymphadenitis without evidence of other diseases 452 
has not been well characterised in dogs. Diagnosis of canine sterile steroid-responsive 453 
lymphadenopathy involves extensive investigations to rule out any detectable underlying 454 
infectious, inflammatory or neoplastic causes. Most cases responded to prednisolone therapy 455 
and the rapid resolution of clinical signs was associated with normalisation of the 456 
lymphadenopathy. In addition, some of the cases relapsed after discontinuation of the 457 
treatment or while decreasing the dosage of the medication, being also suggestive of a 458 
primary immune-mediated disease process.  459 
 460 
In conclusion, idiopathic or primary sterile steroid-responsive lymphadenitis should be 461 
considered a differential diagnosis in young-adult dogs (especially female springer spaniels) 462 
presenting with pyrexia and peripheral and/or internal lymphadenopathy. The suggested 463 
breed predisposition in springer spaniels warrants further study.  464 
 465 
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